Best Treatment Guidelines For Bronchial Asthma

Col SP Rai*, Col AP Patil+, Lt Col V Vardhan†, Maj V Marwah**, M Pethe ++, Maj IM Pandey##

Abstract

Asthma is a common disease worldwide with significant ethnic and regional variations. An increasing morbidity and mortality, as well as health care burden from asthma have been recognized lately. Several evidence based guidelines have been developed with an aim to standardize and improve the quality of management. These guidelines seek to translate the advances in the understanding of pathogenesis of asthma and in the development of new agents and strategies into practical application at all levels of healthcare. These advocate an assessment of the patients to classify the severity of diseases followed by a step-wise approach to treatment. With the current management we hope to achieve minimum or nil day time and night time symptoms, prevent acute exacerbations and attain normal or near normal lung function, thus improving the overall quality of life.

Key Words : Bronchial asthma

Introduction

Numerous evidence based guidelines for diagnosis and management of bronchial asthma are available throughout the world [1-3], because of the differences in the health care infrastructure, risk factors, disease pattern and prevalence. The Indian guidelines for bronchial asthma are discussed.

Definition

Bronchial asthma is a chronic inflammatory disorder of the airways associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing particularly at night or in the early morning. These episodes are usually associated with widespread but variable airflow obstruction that is often reversible either spontaneously or with treatment.

Incidence

The prevalence of asthma worldwide is around 200 million with a mortality of around 0.2 million per year. The estimated burden of asthma in India is more than 15 million. The population prevalence of asthma reported in different field studies and specific population group is reported to be variable [4,5].

Onset of asthma can occur at any age, but children and young adults are commonly affected. Although asthma can not be cured, clinical episode can be prevented and controlled by proper management. The exact cause of asthma is not known. There are a variety of host and the environmental risk factors. The host factors are genetic predisposition, atopy [5], airway hyperresponsiveness, gender and race/ethnicity. The environmental risk factors are indoor and outdoor allergens, occupational sensitizers, tobacco smoke and air pollution [5-7], respiratory infections, parasitic infections, socio economic factors, family size, diet, drugs and obesity.

Diagnosis

Careful history should be taken of isolated wheeze, wheeze with dyspnoea, exercise dyspnoea, wheezing in absence of cold, nocturnal chest tightness, nocturnal cough, nocturnal dyspnoea, chronic phlegm production and chronic cough. The important physical findings are wheezing, hyper inflated chest, tachypnea, tachycardia, use of accessory muscles of respiration, cyanosis, drowsiness and allergic rhinitis or sinusitis.

In the differential diagnosis, always think whether the obstruction is localized or generalized? If generalized, differentiate asthma from chronic obstructive pulmonary disease (COPD) and left ventricular failure (Table 1). Localized obstruction may be due to tumour, foreign body, aspergillosis, mediastinal lymphadenopathy or laryngeal nerve palsy.

The diagnosis of asthma in any patient can be viewed as a two step approach (Fig.1). The first step includes clinical suspicion of the diagnosis and attempts to

*Senior Advisor (Medicine & Respiratory Medicine), +Senior Advisor (Medicine & Respiratory Medicine), †Classified Specialist (Medicine & Respiratory Medicine), ‡Senior Resident (Respiratory Medicine), §§Senior Resident (Respiratory Medicine), ##Resident Respiratory Medicine, Military Hospital (CTC) Pune 40.
Received : 18.05.07; Accepted : 12.06.07
exclude asthma mimics while the next step includes the confirmation of diagnosis in equivocal cases based on laboratory investigations. At the primary and secondary health care levels of regimental medical officer and a physician at a peripheral hospital respectively, the diagnosis is mainly clinical. A "Peak Flow Meter" should be used to confirm the reversibility and severity of the disease. Peak flow meters are commonly available and patient should be instructed to record the peak flow rates in the morning and evening. A diurnal variation of more than 20% is considered diagnostic.

At the tertiary health care level spirometry is recommended. Further skin sensitivity testing may demonstrate the allergens.

**Treatment**

There is no permanent cure for asthma however the disorder can be adequately controlled with drugs. The optimal asthma control [1] would include minimal chronic symptoms, minimal exacerbations, minimal need for use of β2-agonist, no limitations on activities, including exercise and PEFR variability of less than 20 percent.

Assessment of severity is important before treatment is initiated (Table 2) and patient should be placed in the highest category of severity based on any of the clinical features or lung function tests.

**Basic drug therapy**: Asthma is an inflammatory disorder and the aim of treatment is to decrease inflammation by anti-inflammatory drugs and exposure to triggers. The drugs can be grouped under controllers; those which control inflammation and relievers; those which offer symptomatic relief (Table 3).

Inhaled route is the best route of corticosteroid (CS) therapy as it provides targeted drug delivery, acts faster, small dose is required and is easy to take [10,11]. Oral steroids have more side effects and have no superiority compared to inhaled route.

---

**Table 1**

**Difference between Asthma and COPD**

<table>
<thead>
<tr>
<th></th>
<th>Asthma</th>
<th>COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset</td>
<td>Anytime</td>
<td>Mid to late adult life</td>
</tr>
<tr>
<td>Smoking</td>
<td>±</td>
<td>++</td>
</tr>
<tr>
<td>Cough and sputum</td>
<td>Less common</td>
<td>Common</td>
</tr>
<tr>
<td>Dyspnoea on exertion</td>
<td>Variable</td>
<td>Progressive</td>
</tr>
<tr>
<td>Nocturnal symptoms</td>
<td>Common</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Airway obstruction</td>
<td>Diurnal variation</td>
<td>Little variation</td>
</tr>
<tr>
<td>Response to CS</td>
<td>Good</td>
<td>15-20%</td>
</tr>
<tr>
<td>Non specific BHR</td>
<td>Majority of patients</td>
<td>Only in minority of patients</td>
</tr>
</tbody>
</table>

---

**Fig. 1**: Approach to diagnosis of bronchial asthma.
over ICS in management of asthma. However in management of severe acute exacerbations they are beneficial.

**Inhaled corticosteroids (ICS)**

Most effective medication for asthma and first-line therapy [12,13]. They are anti-inflammatory and disease modifying resulting in improved lung function, reduction of symptoms and exacerbations. The dosage of inhaled corticosteroids is given in Table 4.

**Combinations (ICS + long acting ?2 agonist)**

Long acting ?2 agonists are helpful in improving asthma control and airway functions when inhaled corticosteroids are insufficient [14]. Long acting inhaled ?2-agonist (formoterol and salmeterol) should not be used as a monotherapy in asthma as they do not appear to influence the airway inflammation in asthma. They are most effective when combined with inhaled glucocorticosteroids and this combination therapy is the preferred treatment when a medium dose of inhaled glucocorticosteroid alone fails to achieve control of asthma. They have steroid sparing effect and lead to better asthma control.

**Leukotriene Inhibitors**

- New class of asthma medication
- Not superior to inhaled corticosteroids
- Indicated for aspirin induced, exercise induced asthma and add on therapy for severe persistent asthma [15].

**Exacerbation of Asthma**

Exacerbation of asthma is characterized by the worsening of symptoms with increase in dyspnoea, cough and wheeze. There is a decline in lung function, which can be quantitated with measurements of PEF or FEV1. The exacerbations are categorized as severe or non-severe. Severe exacerbation of asthma are characterized by increase in dyspnoea, with patient unable to complete one sentence in one breath (in children: interrupted feeding and agitation), respiratory rate > 30/minute, heart rate > 120/minute, use of accessory muscles of respiration, pulsus paradoxus > 25 mmHg, PEF < 60% personal best or < 100 litres/minute in adults.

In children, the normal respiratory and pulse rates are different from adults and values exceeding normal limits should not be considered abnormal.

**Management of Non-Severe Exacerbations**

Patients with non-severe exacerbations can usually be managed on an outpatient basis, with repeated administration of rapid acting inhaled ?2 agonists (2 puffs...
Bronchial Asthma

Management of Severe Exacerbations

Severe exacerbations of asthma can be life-threatening and should be managed as an emergency. After initial beta-agonist, ipratropium inhalation/nebulization, oxygen and one parenteral dose of steroids the patient should be referred to secondary/tertiary care centre. The important points in the management of acute severe asthma are summarised below:

1. A hand-held chamber is as effective as a nebuliser for the delivery of drugs used in acute asthma.

2. The use of intravenous aminophylline does not result in any additional bronchodilation as compared to inhaled beta-agonists, but the frequency of adverse effects is higher with aminophylline. Thus, it should be used only if patient is not cooperative or inhaled therapy is ineffective.

3. A combination of ipratropium plus salbutamol is better than salbutamol alone in the management of severe exacerbations [16].

4. The use of continuous beta-agonists (defined as truly continuous aerosol delivery of beta-agonist medication using a large volume nebuliser or sufficiently frequent nebulisations so that medication delivery is effectively continuous, i.e. one nebulisation every 15 minutes or four times per hour) in patients with severe acute asthma improves their lung functions and reduces hospitalization in patients who present to the emergency department [17].

5. Glucocorticoids are the mainstay of therapy [18,19] and their use within an hour of presentation significantly reduces the need for hospital admission in patients with acute asthma. There is no advantage of parenteral over oral glucocorticoids except in few circumstances [18]. There is also no advantage of a particular preparation of glucocorticoids in acute asthma, and a maximum dose of 40-60mg/day of prednisolone is given and continued for at least 7-10 days or until recovery.

6. Inhaled corticosteroids have no added benefit when used in addition to oral steroids.

7. There is no evidence to support the use of intravenous \( \beta_2 \)-agonists in acute severe asthma and they should be given by inhalation.

8. In resistant cases administration of a single dose of intravenous magnesium sulphate (2 gm over 20 minutes) improves pulmonary function when used as an adjunct to standard therapy [20]. The treatment should be used with great caution and monitoring.

9. There is no role of routine use of antibiotics except if patient has fever, leukocytosis, purulent sputum or radiographic infiltrates suggestive of an infection.

10. A written advice mentioning the drugs, their dosages, frequency and requirement for follow-up visits is a must.

The Stepwise Management

**Hour 1**: (i) oxygen administration, (ii) hydration (intravenous fluids), (iii) up to four doses of inhaled salbutamol with ipratropium, (iv) intravenous hydrocortisone (100mg) or oral prednisolone (40-60mg).

**Hour 2**: (i) four more doses of inhaled salbutamol with ipratropium, (ii) intravenous aminophylline, (iii) intravenous magnesium sulphate 2gm, (iv) subcutaneous terbutaline 0.3-0.5mg (0.01mg/kg-child)

Patient Referral

The indications for referral of a patient with suspected/established asthma to an advanced center are atypical signs or symptoms (significant expectoration > 60ml/day, hemoptysis, monophonic wheeze), failure to respond to treatment for over one month, severe persistent or life threatening asthma (cyanosis, mental obtundation), acute severe asthma not responding within two hours of intensive therapy, other complicating conditions and in cases of doubtful diagnosis.

Environmental control

Pharmacological therapy alone will not give a good control of asthma. Mattress and pillow covers should be free of mites. Removal of carpeting and vacuuming of furniture helps. Animal pets at times are the offending allergens and may have to be removed from home.

Asthma education: Asthma education is an important but often neglected aspect of asthma management in our country [21]. It is not only the patient and their family members but also the general practitioners at the peripheral care levels who need to continuously keep themselves updated on asthma [22,23]. There is little doubt that efforts to improve the implementation of evidence based guidelines by clinicians will increase the quality of patient care.

Conflicts of Interest

None identified
References


ANNOUNCEMENT
BEST REFEREE AWARD : MJAFI

The Best Referee Award has been instituted with effect from 2006 to appreciate the contribution made by the referees in publication of the articles in MJAFI. The award will be given during the AFMRC annually. The criteria for selection of Best Referee would be:

(a) Usage of email in all correspondence
(b) First response within two weeks of receipt of article
(c) Subsequent responses within one week
(d) Most constructive comments